胆管癌药物治疗现状:最新进展与关键局限
Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.
胆管癌(CCA)是一种起源于胆道系统的高度致死性、异质性恶性肿瘤。
65.6分
★★★☆☆
FRONTIER PAPERS
Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.
胆管癌(CCA)是一种起源于胆道系统的高度致死性、异质性恶性肿瘤。
The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma.
尽管罕见,CCA 的 5 年生存率很低,在过去 10-20 年间仍是原发性肝肿瘤相关死亡的主要原因。
Advances in immunotherapy for biliary tract cancers.
胆道癌(BTC)是一种异质性较强、预后较差的疾病,包括胆囊癌(GBC)、肝内胆管癌(ICC)和肝外胆管癌(ECC)。
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma.
肝细胞癌(HCC)和胆管癌(CCA)构成原发性肝癌中高度恶性的类型。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。